Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 90

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 90
---
 on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of
said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2024 contains
an explanatory paragraph regarding our ability to continue as a going concern.

PKF Littlejohn LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

The
financial statements of Biodexa Pharmaceuticals PLC as of December 31, 2023, and for each of the three years in the period then ended,
incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on a report of Forvis
Mazars LLP (then-named Mazars LLP), an independent registered public accounting firm, given on authority of said firm as experts in auditing
and accounting. The report on the financial statements for the year ended December 31, 2023, contains an explanatory paragraph in Note 2 regarding our ability to continue as a going concern.

Forvis
Mazars LLP, London, United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC
a registration statement on Form F-1, including amendments and relevant exhibits and schedules, under the Securities Act covering the
Ordinary Shares represented by Depositary Shares to be sold in this offering. This prospectus, which constitutes a part of the registration
statement, summarizes material provisions of contracts and other documents that we refer to in the prospectus. Since this prospectus does
not contain all of the information contained in the registration statement, you should read the registration statement and its exhibits
and schedules for further information with respect to us and our Ordinary Shares and the Depositary Shares.

We are subject to periodic
reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers. Accordingly, we are required
to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt
from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy
rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our “insiders” are exempt from the reporting and short-swing
profit recovery provisions contained in Section